Abbott Laboratories Peer Comparison
| Metric | Value | Ranking | ||||||
|---|---|---|---|---|---|---|---|---|
| Market Cap | $174.1 Billion | 4/6 | LLY $860.1B |
JNJ $400.0B |
ABBV $327.9B |
ABT $174.1B |
MDT $113.0B |
BMY $100.8B |
| Gross Margin | 56% | 5/6 | LLY 81% |
JNJ 79% |
ABBV 67% |
MDT 60% |
ABT 56% |
BMY 56% |
| Profit Margin | 12% | 5/6 | LLY 26% |
JNJ 21% |
BMY 14% |
MDT 13% |
ABT 12% |
ABBV 11% |
| EBITDA margin | 15% | 6/6 | BMY 42% |
LLY 42% |
ABBV 41% |
JNJ 29% |
MDT 27% |
ABT 15% |
| Quarterly Revenue | $10.0 Billion | 5/6 | JNJ $22.4B |
ABBV $12.3B |
BMY $12.2B |
LLY $11.3B |
ABT $10.0B |
MDT $7.9B |
| Quarterly Earnings | $1.2 Billion | 5/6 | JNJ $4.7B |
LLY $3.0B |
BMY $1.7B |
ABBV $1.4B |
ABT $1.2B |
MDT $1.0B |
| Quarterly Free Cash Flow | $627.0 Billion | 4/6 | JNJ $4.7B |
ABBV $3.8B |
BMY $2.1B |
ABT $627.0M |
MDT $466.0M |
LLY $63.4M |
| Trailing 4 Quarters Revenue | $40.3 Billion | 4/6 | JNJ $86.6B |
ABBV $54.4B |
BMY $46.5B |
ABT $40.3B |
LLY $38.9B |
MDT $32.6B |
| Trailing 4 Quarters Earnings | $5.6 Billion | 4/6 | JNJ $22.4B |
ABBV $12.3B |
BMY $12.2B |
LLY $11.3B |
ABT $10.0B |
MDT $7.9B |
| Quarterly Earnings Growth | -7% | 4/6 | ABBV 473% |
LLY 68% |
MDT 32% |
ABT -7% |
JNJ -9% |
BMY -19% |
| Annual Earnings Growth | 27% | 2/6 | JNJ 670% |
ABT 27% |
LLY 27% |
MDT -9% |
ABBV -22% |
BMY -174% |
| Quarterly Revenue Growth | 2% | 3/6 | BMY 9% |
MDT 3% |
ABT 2% |
ABBV 1% |
LLY 0% |
JNJ -12% |
| Annual Revenue Growth | 1% | 3/6 | LLY 86% |
BMY 3% |
ABT 1% |
MDT -2% |
ABBV -6% |
JNJ -13% |
| Cash On Hand | $6.3 Billion | 4/6 | JNJ $24.9B |
ABBV $18.1B |
BMY $6.3B |
ABT $6.3B |
LLY $3.2B |
MDT $1.3B |
| Short Term Debt | $2.0 Billion | 5/6 | ABBV $10.2B |
JNJ $9.9B |
LLY $5.2B |
BMY $3.7B |
ABT $2.0B |
MDT $1.6B |
| Long Term Debt | $12.6 Billion | 6/6 | ABBV $63.8B |
BMY $48.9B |
JNJ $31.6B |
MDT $26.3B |
LLY $23.7B |
ABT $12.6B |
| PE | 30.92 | 3/6 | LLY 117.15 |
ABBV 54.72 |
ABT 30.92 |
MDT 28.77 |
JNJ 10.52 |
BMY -1.00 |
| PS | 4.32 | 4/6 | LLY 22.10 |
ABBV 6.03 |
JNJ 4.62 |
ABT 4.32 |
MDT 3.47 |
BMY 2.17 |
| PB | 4.46 | 5/6 | LLY 63.08 |
ABBV 40.75 |
BMY 5.91 |
JNJ 5.59 |
ABT 4.46 |
MDT 2.35 |
| PC | 27.70 | 3/6 | LLY 266.82 |
MDT 86.21 |
ABT 27.70 |
ABBV 18.15 |
JNJ 16.08 |
BMY 16.02 |
| Liabilities to Equity | 0.86 | 6/6 | ABBV 17.59 |
BMY 4.56 |
LLY 4.29 |
JNJ 1.53 |
MDT 0.87 |
ABT 0.86 |
| ROA | 0.08 | 3/6 | JNJ 21% | LLY 10% | ABT 8% | ABBV 4% | MDT 4% | BMY -7% |
| ROE | 0.15 | 4/6 | ABBV 75% |
LLY 54% |
JNJ 53% |
ABT 15% |
MDT 8% |
BMY -38% |
| Current Ratio | 2.17 | 1/6 | ABT 2.17 |
MDT 2.16 |
JNJ 1.65 |
LLY 1.23 |
BMY 1.22 |
ABBV 1.06 |
| Quick Ratio | 0.20 | 2/6 | LLY 117.15 |
ABBV 54.72 |
ABT 30.92 |
MDT 28.77 |
JNJ 10.52 |
BMY -1.00 |
| Long Term Debt to Equity | 0.32 | 6/6 | ABBV} 7.97 |
BMY} 2.87 |
LLY} 1.75 |
MDT} 0.55 |
JNJ} 0.44 |
ABT} 0.32 |
| Debt to Equity | 0.38 | 6/6 | ABBV 9.24 |
BMY 3.17 |
LLY 2.13 |
JNJ 0.58 |
MDT 0.58 |
ABT 0.38 |
| Burn Rate | -28.63 | 6/6 | BMY 5.24 |
ABBV 4.84 |
MDT 3.30 |
LLY -4.43 |
JNJ -26.00 |
ABT -28.63 |
| Cash to Cap | 0.04 | 4/6 | BMY 0.06 |
ABBV 0.06 |
JNJ 0.06 |
ABT 0.04 |
MDT 0.01 |
LLY 0.00 |
| CCR | 0.51 | 4/6 | ABBV 2.81 |
BMY 1.23 |
JNJ 0.99 |
ABT 0.51 |
MDT 0.45 |
LLY 0.02 |
| EV to EBITDA | 125.78 | 2/6 | LLY} 187.72 |
ABT} 125.78 |
ABBV} 75.82 |
MDT} 66.40 |
JNJ} 64.52 |
BMY} 28.87 |
| EV to Revenue | 4.52 | 4/6 | LLY 22.76 |
ABBV 7.06 |
JNJ 4.81 |
ABT 4.52 |
MDT 4.28 |
BMY 3.19 |